A Study to Describe the Diagnosis, Anti-Cancer Treatment and Clinical Outcome in Patients With Newly Diagnosed Breast Cancer in Latin America
NCT ID: NCT04158258
Last Updated: 2025-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
2907 participants
OBSERVATIONAL
2020-02-21
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment
NCT01702571
A Study of Herceptin (Trastuzumab) in Combination Chemotherapy in Women With Locally Advanced Breast Cancer
NCT01998906
A Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function
NCT01513083
A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)
NCT02819882
An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
NCT01215123
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bevacizumab
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Bevacizumab
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Trastuzumab
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Trastuzumab
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Ado-trastuzumab emtamsine
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Ado-trastuzumab emtamsine
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Pertuzumab
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Pertuzumab
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Atezolizumab
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Atezolizumab
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Capecitabine
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Capecitabine
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bevacizumab
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Trastuzumab
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Ado-trastuzumab emtamsine
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Pertuzumab
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Atezolizumab
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Capecitabine
Dosing and treatment duration of any studied medicinal products collected are at the discretion of the physician in accordance with local clinical practice and local labeling.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Patients not receiving the Roche studied medicinal product, but a biosimilar
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Latin American Cooperative Oncology Group
OTHER
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Instituto Alexander Fleming
Buenos Aires, , Argentina
Instituto Oncologico De Cordoba
Córdoba, , Argentina
Hospital Privado Centro Medico de Cordoba
Córdoba, , Argentina
Hospital de Morón
Morón, , Argentina
Instituto de Oncología de Rosario
Rosario, , Argentina
Sanatorio de la Mujer
Rosario, , Argentina
Crio - Centro Regional Integrado de Oncologia
Fortaleza, Ceará, Brazil
Hospital do Câncer de Londrina
Londrina, Paraná, Brazil
Hospital Jardim Amália
Volta Redonda, Rio de Janeiro, Brazil
Inst. de Vita
Caxias do Sul, Rio Grande do Sul, Brazil
Centro de Pesquisa em Oncologia
Porto Alegre, Rio Grande do Sul, Brazil
Instituto Nacional de Cancer - INCa
Rio de Janeiro, , Brazil
Instituto Brasileiro De Controle Do Câncer - IBCC
São Paulo, , Brazil
Clinica Las Condes
Santiago, , Chile
Instituto Nacional del Cancer
Santiago, , Chile
Hospital Dr. Hernan Henriquez Aravena
Temuco, , Chile
Organización Clínica Bonnadona Prevenir S.A.S
Barranquilla, , Colombia
Inst. Nacional de Cancerologia
Bogotá, , Colombia
Centro Medico Imbanaco
Cali, , Colombia
Fundacion Cardiovascular de Colombia - Instituto del Corazón
Floridablanca, , Colombia
Hospital Hermanos Ameijeiras
La Habana, , Cuba
Instituto de Oncologia Dr. Heriberto Pieter
Santo Domingo, , Dominican Republic
Grupo Angeles
Guatemala City, , Guatemala
Instituto Nacional de Cancerologia
Mexico City, Mexico CITY (federal District), Mexico
Hospital Zambrano Hellion TecSalud
Monterrey, Nuevo León, Mexico
Centro Oncologico Estatal ISSEMYM
Toluca, , Mexico
Instituto Nacional de Enfermedades Neoplasicas
Lima, , Peru
Clinica Internacional, Sede San Borja
Lima, , Peru
Aliada Centro Oncologico
Lima, , Peru
Sanatorio CASMU
Montevideo, , Uruguay
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MO39485
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.